Personalized Oncology in Gastrointestinal Cancer: Emerging Therapies and Challenges
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".
Deadline for manuscript submissions: closed (20 April 2026) | Viewed by 696
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue on “Personalized Oncology in Gastrointestinal Cancer: Emerging Therapies and Challenges” will mainly focus on analyzing present and future approaches for the treatment of gastrointestinal (GI) cancer patients, with a glimpse into novel perspectives and future challenges in clinical practice. GI cancers are one of the most common worldwide cause of cancer-related death. They include a wide spectrum of neoplasms, including esophageal, gastric, hepatic, biliary, pancreatic, small bowel and large bowel as well as rectal cancers. In the last decade, significant improvements have been made in the prognosis of patients affected by these tumors thanks to the development of new treatments, which include cytotoxic drugs, targeted therapies, and immunotherapy. Recently, emerging and novel biomarkers have been identified and validated with a huge impact on patients’ outcomes and improving the treatment landscape. Despite these advances, GI cancers still represent a major public health problem worldwide; hence, it is mandatory to develop novel therapeutic approaches. We cordially invite experts in the field to submit original research or review articles to better understand and explore this important topic.
We look forward to receiving your contributions.
Dr. Carmelo Laface
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gastrointestinal cancers
- immunotherapy
- targeted therapy
- chemotherapy
- microsatellite instability
- driver mutations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
